{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:57:12Z","timestamp":1794412632418,"version":"4.9.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025077","name":"Faculty of Medicine, University of Ottawa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000014","name":"Canadian Blood Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000014","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jcyt.2025.06.006","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:17:19Z","timestamp":1749813439000},"page":"1179-1189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["CAR-NK cells to treat patients with cancer: a systematic scoping review of published studies and registered clinical trials"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8280-8844","authenticated-orcid":false,"given":"Simrit","family":"Rana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0163-4813","authenticated-orcid":false,"given":"Lilli","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan M.","family":"Kirkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0388-5812","authenticated-orcid":false,"given":"Risa","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinad","family":"Maganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Seftel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-8289","authenticated-orcid":false,"given":"David S.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.06.006_bib0001","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0002","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jtct.2023.07.002","article-title":"Updated indications for immune effector cell therapy: 2023 guidelines from the American society for transplantation and cellular therapy","volume":"29","author":"Kanate","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0003","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0004","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-Cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0005","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0006","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-Cell Therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0007","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jtct.2023.01.021","volume":"29","author":"Nikiforow","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0008","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3389\/fimmu.2015.00578","article-title":"The application of natural killer cell immunotherapy for the treatment of cancer","volume":"6","author":"Rezvani","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0009","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0010","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0011","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0012","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jcyt.2024.11.004","article-title":"Efficacy of chimeric antigen receptor engineered natural killer cells in the treatment of hematologic malignancies: a systematic review and meta-analysis of preclinical studies","volume":"27","author":"Bastin","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0013","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-021-03209-4","article-title":"Engineering the next generation of CAR-NK immunotherapies","volume":"114","author":"Biederstadt","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0016","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0017","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0018","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0019","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0020","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/jcrt.JCRT_190_20","article-title":"Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis","volume":"16","author":"Li","year":"2020","journal-title":"J Cancer Res therapeut"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221094244","article-title":"Cytokine release syndrome after modified CAR-NK therapy in an advanced non-small cell lung cancer patient: a case report","volume":"31","author":"Zhang","year":"2022","journal-title":"Cell Transplant"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0022","article-title":"Relapsed\/refractory diffuse large B cell lymphoma with cardiac involvement: A case report and literature review","volume":"13","author":"Yang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0023","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13287-023-03272-0","article-title":"Intrathecal CAR-NK cells infusion for isolated CNS relapse after allogeneic stem cell transplantation: case report","volume":"14","author":"Yuan","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0024","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s12024-023-00693-4","article-title":"Case report: sudden death following the administration of CAR-NK cells for lung cancer immunotherapy","volume":"20","author":"Zhao","year":"2024","journal-title":"Forensic Sci Med Pathol"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","article-title":"Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial","volume":"14","author":"Huang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape-Lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0028","article-title":"Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia","volume":"10","author":"Martinez","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0029","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-delta CAR-T cells show car-directed and independent activity against Leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0030","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0031","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0032","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/stcltm\/szab009","article-title":"Definition and characteristics of mesenchymal stromal cells in preclinical and clinical studies: a scoping review","volume":"11","author":"Renesme","year":"2022","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0033","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jcyt.2022.10.003","article-title":"Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?","volume":"25","author":"Kirkham","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0034","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","article-title":"The NK-92 cell line \u201330 years later: its impact on natural killer cell research and treatment of cancer","volume":"25","author":"Klingemann","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.17186","article-title":"Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity","volume":"193","author":"Rafei","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0036","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0037","article-title":"Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture","author":"Li","year":"2025","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0038","unstructured":"International Society for Stem Cell Research. Appendix I: recommended standard characterization of stem cells. 2023; www.isscr.org\/standaardsdocument\/appendix1 [accessed February 12, 2025]."},{"key":"10.1016\/j.jcyt.2025.06.006_bib0039","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.3267","article-title":"Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies","volume":"19","author":"Lee","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0040","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jcyt.2022.10.003","article-title":"Mesenchymal stem\/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19","volume":"25","author":"Kirkham","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0041","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2025.06.006_bib0042","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925007455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925007455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:01:17Z","timestamp":1778943677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925007455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1465324925007455"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.06.006","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-NK cells to treat patients with cancer: a systematic scoping review of published studies and registered clinical trials","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}